drugset / Trial / NCT03561181

Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months

NCT03561181 ↗

Phase 1 Completed 180 enrolled Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate safety of S.flexneriza-S.sonnei Bivalent Conjugate Vaccine in healthy volunteers aged above 3 Months.

Timeline

Start
2017-07-18
Primary completion
2018-01-28
Completion
2018-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine Vaccine 5 ug Intramuscular
Subject S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine Vaccine 10 ug Intramuscular

Indications